PL1853305T3 - Szczepionka na bazie peptydu surwiwina - Google Patents

Szczepionka na bazie peptydu surwiwina

Info

Publication number
PL1853305T3
PL1853305T3 PL06704603T PL06704603T PL1853305T3 PL 1853305 T3 PL1853305 T3 PL 1853305T3 PL 06704603 T PL06704603 T PL 06704603T PL 06704603 T PL06704603 T PL 06704603T PL 1853305 T3 PL1853305 T3 PL 1853305T3
Authority
PL
Poland
Prior art keywords
peptide vaccine
survivin peptide
survivin
vaccine
peptide
Prior art date
Application number
PL06704603T
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Publication of PL1853305T3 publication Critical patent/PL1853305T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06704603T 2005-02-04 2006-02-03 Szczepionka na bazie peptydu surwiwina PL1853305T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500173 2005-02-04
US65075105P 2005-02-07 2005-02-07
EP06704603.7A EP1853305B1 (en) 2005-02-04 2006-02-03 Survivin peptide vaccine
PCT/DK2006/000061 WO2006081826A2 (en) 2005-02-04 2006-02-03 Survivin peptide vaccine

Publications (1)

Publication Number Publication Date
PL1853305T3 true PL1853305T3 (pl) 2015-02-27

Family

ID=39042995

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06704603T PL1853305T3 (pl) 2005-02-04 2006-02-03 Szczepionka na bazie peptydu surwiwina

Country Status (15)

Country Link
US (1) US20110091489A1 (pl)
EP (3) EP1853305B1 (pl)
JP (2) JP2008528643A (pl)
KR (1) KR20070108536A (pl)
CN (3) CN101111260B (pl)
AU (1) AU2006209951B2 (pl)
BR (1) BRPI0607326B8 (pl)
CA (1) CA2593714C (pl)
DK (1) DK1853305T3 (pl)
ES (1) ES2523172T3 (pl)
MX (1) MX2007009219A (pl)
PL (1) PL1853305T3 (pl)
RU (1) RU2396088C2 (pl)
WO (1) WO2006081826A2 (pl)
ZA (1) ZA200705943B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) * 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
NO2280721T3 (pl) 2008-04-17 2018-04-14
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
FR2955775B1 (fr) 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
EP2978450B1 (en) 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
WO2015090572A1 (en) * 2013-12-16 2015-06-25 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
CN107531736B (zh) 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CA3005127C (en) 2015-11-18 2023-01-24 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
WO2017147263A1 (en) * 2016-02-23 2017-08-31 National Health Research Institutes Lipidated survivin and the use thereof for prevention and treatment of cancers
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
CN107228894B (zh) * 2017-01-24 2019-03-19 浙江海隆生物科技有限公司 一种油乳剂蛋白亚单位疫苗中蛋白含量和纯度的检测方法及其应用
AU2018226566B2 (en) 2017-03-03 2025-01-23 Treos Bio Limited Population-based immunogenic peptide identification platform
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
TWI837109B (zh) * 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
MA53543A (fr) * 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU679902B2 (en) * 1992-09-30 1997-07-17 Ohio State University Research Foundation, The Vaccines and antigenic conjugates
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CA2271783C (en) 1996-11-20 2013-04-16 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
EP1294905A1 (en) * 2000-06-26 2003-03-26 SmithKline Beecham Biologics SA Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
WO2002055100A2 (en) * 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
JP2002365286A (ja) * 2000-11-13 2002-12-18 Kyogo Ito 細胞性免疫検出法およびその医薬への応用
JP4780540B2 (ja) * 2001-03-23 2011-09-28 北海道公立大学法人 札幌医科大学 サバイビン由来癌抗原ペプチド
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6780121B2 (en) * 2002-09-09 2004-08-24 Paul J. Herber Golf club head construction
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
US7221826B2 (en) * 2002-10-08 2007-05-22 Tdk Corporation Spot-size transformer, method of producing spot-size transformer and waveguide-embedded optical circuit using spot-size transformer
ES2323692T3 (es) * 2002-12-02 2009-07-23 Resistentia Holding Ab Metodos y materiales para tratar afecciones inflamatorias usando un polipeptido que comprende un segmento de aminoacidos c5 autogenicos y un segmento de aminoacidos no autogenicos.
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2530184C (en) * 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
EP2087904B1 (en) * 2003-11-19 2013-08-28 Survac ApS Therapeutic use of peptides derived from Bcl-XL protein in cancer patients

Also Published As

Publication number Publication date
EP1853305B1 (en) 2014-08-20
AU2006209951A1 (en) 2006-08-10
EP1853305A2 (en) 2007-11-14
ZA200705943B (en) 2008-12-31
JP5631357B2 (ja) 2014-11-26
WO2006081826A2 (en) 2006-08-10
RU2396088C2 (ru) 2010-08-10
EP2329841A1 (en) 2011-06-08
BRPI0607326B1 (pt) 2021-01-19
BRPI0607326A2 (pt) 2009-09-01
MX2007009219A (es) 2008-01-16
RU2007133103A (ru) 2009-03-10
BRPI0607326B8 (pt) 2021-05-25
CN103169958A (zh) 2013-06-26
HK1112367A1 (en) 2008-08-29
JP2008528643A (ja) 2008-07-31
DK1853305T3 (en) 2014-12-01
CN103143004A (zh) 2013-06-12
US20110091489A1 (en) 2011-04-21
CA2593714A1 (en) 2006-08-10
ES2523172T3 (es) 2014-11-21
CA2593714C (en) 2013-09-10
EP2329840A1 (en) 2011-06-08
CN101111260A (zh) 2008-01-23
WO2006081826A3 (en) 2007-02-15
KR20070108536A (ko) 2007-11-12
CN101111260B (zh) 2013-03-20
JP2012149101A (ja) 2012-08-09
AU2006209951B2 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
ZA200705943B (en) Survivin peptide vaccine
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
IL219048A (en) Peptide compounds derived from urcl10
ZA200803525B (en) New cyclic peptide compounds
GB0508863D0 (en) Peptide
GB0409940D0 (en) Vaccine
ZA200802571B (en) GDNF derived peptides
ZA200709207B (en) Vaccine
GB0519161D0 (en) Adjuvanted vaccine
GB0810662D0 (en) Vaccine
GB0526019D0 (en) Peptides
GB0515135D0 (en) Vaccine
GB2443591B (en) Adjuvanted vaccine
GB0516527D0 (en) Peptides
GB0516944D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0526412D0 (en) Vaccine
IL180491A0 (en) Cyclic peptides
GB0512969D0 (en) Peptides
GB0523953D0 (en) Peptides
IL186591A0 (en) Vaccine
GB0526232D0 (en) Vaccine
GB0521164D0 (en) Vaccine
GB0513189D0 (en) Vaccine